| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1016169202830 |
| P698 | PubMed publication ID | 12134959 |
| P2093 | author name string | Paul W Buehler | |
| Win L Chiou | |||
| P2860 | cites work | Oxidative metabolism of zolpidem by human liver cytochrome P450S | Q70978034 |
| The absorption of disopyramide in animals determined using a stable isotope co-administration technique | Q71290638 | ||
| Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals | Q72127195 | ||
| Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities | Q72658479 | ||
| Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man | Q72847659 | ||
| Similarity in the linear and non-linear oral absorption of drugs between human and rat | Q73244489 | ||
| Species differences in oral bioavailability of methotrexate between rats and monkeys | Q73570068 | ||
| The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology | Q73627828 | ||
| Allometric Analysis of Organ Extraction Ratios | Q73909915 | ||
| Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics | Q73933451 | ||
| Comparative in vitro metabolism of indinavir in primates--a unique stereoselective hydroxylation in monkey | Q93930470 | ||
| Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats | Q34067981 | ||
| Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem | Q36071594 | ||
| The absolute oral bioavailability of selected drugs. | Q38625999 | ||
| Pharmacokinetics and toxicity testing | Q40182378 | ||
| Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals | Q40926487 | ||
| Species similarities and differences in pharmacokinetics. | Q41001138 | ||
| We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept | Q41133842 | ||
| Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans | Q42549049 | ||
| Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. | Q44994091 | ||
| Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans | Q51557257 | ||
| New perspectives on the theory of permeability and resistance in the study of drug transport and absorption | Q52299578 | ||
| Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey | Q53020532 | ||
| Biotransformation of the antidepressant DL-rolipram. I. Isolation and identification of metabolites from rat, monkey, and human urine | Q53022042 | ||
| Pharmacokinetics of coumarin upon i.v. administration in man | Q54164207 | ||
| Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species | Q67823256 | ||
| Pharmacokinetics of coumarin and 7-hydroxycoumarin in the rhesus monkey after intravenous and peroral administration | Q68011282 | ||
| Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences | Q68460180 | ||
| Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey | Q70978023 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 868-874 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Comparison of oral absorption and bioavailablity of drugs between monkey and human | |
| P478 | volume | 19 |
| Q89575961 | A Novel Systematic Approach for Selection of Prodrugs Designed to Improve Oral Absorption |
| Q30940461 | Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? |
| Q42744069 | Animal versus human oral drug bioavailability: do they correlate? |
| Q47623306 | Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study |
| Q42684820 | Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers |
| Q38151571 | Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics |
| Q79991796 | Development and validation of a physiology-based model for the prediction of oral absorption in monkeys |
| Q81255843 | Development of a high-throughput in vitro assay using a novel Caco-2/rat hepatocyte system for the prediction of oral plasma area under the concentration versus time curve (AUC) in rats |
| Q53617590 | Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. |
| Q30782163 | Evaluation of rat intestinal absorption data and correlation with human intestinal absorption |
| Q38730618 | Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. |
| Q33488925 | Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research |
| Q51468169 | Gastric pH and gastric residence time in fasted and fed conscious cynomolgus monkeys using the Bravo pH system |
| Q37600381 | Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination |
| Q38011598 | Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms |
| Q27489828 | Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034 |
| Q48700894 | Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. |
| Q39038877 | Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions |
| Q84948141 | Pharmacokinetic modeling: Prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans |
| Q44738634 | Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase |
| Q26764739 | Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models |
| Q45378089 | Prediction of In Vivo Hepatic Clearance and Half-Life of Drug Candidates in Human Using Chimeric Mice with Humanized Liver |
| Q36988426 | Prediction of human pharmacokinetics - renal metabolic and excretion clearance |
| Q39805145 | Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance |
| Q36885247 | Prediction of human pharmacokinetics--gastrointestinal absorption |
| Q38177366 | Pros and cons of methods used for the prediction of oral drug absorption. |
| Q46977325 | Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human |
| Q31049599 | Recent advances in pharmacokinetic extrapolation from preclinical data to humans |
| Q46484127 | Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. |
| Q46762434 | The effect of the Pheroid delivery system on the in vitro metabolism and in vivo pharmacokinetics of artemisone |
| Q97093738 | The past, present and future of intestinal in vitro cell systems for drug absorption studies |
| Q39809409 | The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans |
| Q30670381 | The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. |
| Q37265500 | Towards quantitative prediction of oral drug absorption |
| Q30388503 | Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals |
| Q36535786 | Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. |
Search more.